Pliant Therapeutics links early immune biomarker activation to clinical response in PLN-101095 trial
PLRX•PLRX•PLRX•PLRX•Pliant Therapeutics said early immune activation during Phase 1 monotherapy with PLN-101095 was associated with later clinical response after pembrolizumab initiation. The company also presented preclinical combination-treatment data and said its FORTIFY Phase 1b expansion is enrolling patients with advanced solid tumors resistant to immune checkpoint inhibitors.
Pliant Therapeutics presented clinical biomarker analyses and preclinical data for PLN-101095 at the 2026 Society for Immunotherapy of Cancer annual meeting. Early immune activation during Phase 1 monotherapy was associated with subsequent clinical response following pembrolizumab initiation. Preclinical combination treatment improved anti-tumor activity and survival, and the ongoing FORTIFY Phase 1b expansion is enrolling patients with advanced solid tumors resistant to immune checkpoint inhibitors, including non-small cell lung cancer, high tumor mutational burden tumors and clear cell renal cell carcinoma.
